Summary
CBD (Cannabidiol) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Anxiety Disorders. ClinicalTrials.gov lists 8 registered trials linking CBD (Cannabidiol) to Anxiety Disorders: 2 are currently recruiting; 1 is active or not yet recruiting; 2 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT03549819). The largest enrolment is 200000 participants (NCT03944447). Registration activity spans 2018 to 2026. No published literature item is linked to CBD (Cannabidiol) and Anxiety Disorders in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Anxiety ranks 535 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: GAD: spontaneous remission in ~25-30% at 1 year without treatment; social anxiety: 36% remission at 12 years untreated; panic disorder: 50-65% spontaneous partial remission but relapse common; 40-60% remain symptomatic at 5 years.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 28.0 (trials 23.0, literature 0.0, tier 5, approved bonus 0.0) |
| Registered trials | 8 total: 2 recruiting, 1 active / not yet recruiting, 2 completed, 3 other |
| Linked publications | 0 |
| Agent type | Supplement (Nutraceutical) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Anxiety: a look at epidemiological factors and alternate treatments · Halma M, Covarrubias A, Selem E, Varon J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03549819 | Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 2021 | status unknown | Phase 3 | 50 |
| NCT03948074 | Cannabis For Cancer-Related Symptoms 2021 | completed | Phase 2 | 91 |
| NCT07651930 | Full-Spectrum Cannabidiol Oil for Anxiety and Depressive Symptoms in Parkinson's Disease 2023 | completed | Phase 2 | 27 |
| NCT06261502 | Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome 2025 | not yet recruiting | Phase 2 | 40 |
| NCT04286594 | A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety 2021 | terminated | Phase 2 | 15 |
| NCT03944447 | Outcomes Mandate National Integration With Cannabis as Medicine 2018 | status unknown | Phase 2 | 200,000 |
| NCT05283382 | Cannabidiol Effects on Learning and Anxiety 2024 | recruiting | Early Phase 1 | 160 |
| NCT07656350 | Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) Study 2026 | recruiting | Not applicable | 60 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: Anxiety: a look at epidemiological factors and alternate treatments · Halma M, Covarrubias A, Selem E, Varon J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is CBD (Cannabidiol) approved for Anxiety Disorders?
CBD (Cannabidiol) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Anxiety Disorders. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is CBD (Cannabidiol) in clinical trials for Anxiety Disorders?
ClinicalTrials.gov lists 8 registered trials linking CBD (Cannabidiol) to Anxiety Disorders: 2 are currently recruiting; 1 is active or not yet recruiting; 2 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT03549819). The largest enrolment is 200000 participants (NCT03944447). Registration activity spans 2018 to 2026.
What does the evidence show for CBD (Cannabidiol) in Anxiety Disorders?
CBD (Cannabidiol) has 2 completed registered trials for Anxiety Disorders but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.